Early colorectal cancer refers to cancer in the colorectum that is confined to the mucosa or submucosa and does not invade the muscularis propria, irrespective of lymph node or distant metastasis. As the number of persons undergoing screening colonoscopy increases, the proportion of patients diagnosed with precancerous colorectal lesions and early colorectal cancer also increases. In the last decade, innovative optical technologies for endoscopic diagnosis have been introduced and endoscopic treatment techniques such as endoscopic submucosal dissection have provided major breakthroughs in the management of early colorectal cancer. With these remarkable developments, endoscopic treatment has established itself as an alternative to surgical resection in the treatment of early colorectal cancer. This review will discuss the endoscopic diagnosis and treatment of early colorectal cancer. Furthermore, the unmet needs in this field and the latest research addressing those issues will be summarized.
Citations
Citations to this article as recorded by
Artificial Intelligence Models May Aid in Predicting Lymph Node Metastasis in Patients with T1 Colorectal Cancer Ji Eun Baek, Hahn Yi, Seung Wook Hong, Subin Song, Ji Young Lee, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Seung-Jae Myung, Suk-Kyun Yang, Namkug Kim, Jeong-Sik Byeon Gut and Liver.2025; 19(1): 69. CrossRef
Case report: Successful treatment of advanced colon cancer in an eighty-year-old man with long-term and multi-stage endoscopic minimally invasive therapy Nana Zhang, Lulu Zhu, Yan Liu, Xiaolong Chen, Bifang Zhang, Chunhong Wen, Huayu Zhang, Qinglin Tang, Mingqing Zhang Frontiers in Oncology.2024;[Epub] CrossRef
Prediction of Lymph Node Metastasis in T1 Colorectal Cancer Using Artificial Intelligence with Hematoxylin and Eosin-Stained Whole-Slide-Images of Endoscopic and Surgical Resection Specimens Joo Hye Song, Eun Ran Kim, Yiyu Hong, Insuk Sohn, Soomin Ahn, Seok-Hyung Kim, Kee-Taek Jang Cancers.2024; 16(10): 1900. CrossRef
Influence of Certification Program on Treatment Quality and Survival for Rectal Cancer Patients in Germany: Results of 13 Certified Centers in Collaboration with AN Institute Mihailo Andric, Jessica Stockheim, Mirhasan Rahimli, Sara Al-Madhi, Sara Acciuffi, Maximilian Dölling, Roland Siegfried Croner, Aristotelis Perrakis Cancers.2024; 16(8): 1496. CrossRef
Screening and surveillance for hereditary colorectal cancer Hee Man Kim, Tae Il Kim Intestinal Research.2024; 22(2): 119. CrossRef
The Usefulness of Vitamin K-Dependent Proteins in the Diagnosis of Colorectal Carcinoma Mirela-Georgiana Perné, Adela-Viviana Sitar-Tăut, Olga Hilda Orășan, Vasile Negrean, Călin Vasile Vlad, Teodora-Gabriela Alexescu, Mircea Vasile Milaciu, Lorena Ciumărnean, Răzvan Dan Togănel, Gabriel Emil Petre, Ioan Șimon, Alexandra Crăciun International Journal of Molecular Sciences.2024; 25(9): 4997. CrossRef
Strategies to improve screening colonoscopy quality for the prevention of colorectal cancer Joo Hye Song, Eun Ran Kim The Korean Journal of Internal Medicine.2024; 39(4): 547. CrossRef
Patient and procedural factors associated with true histology rates in patients undergoing colonoscopy with computer-aided detection of polyps Aasma Shaukat, David R. Lichtenstein, Daniel C. Chung, Caitlyn Seidl, Yeli Wang, Emma E. Navajas, Daniel R. Colucci, Shrujal Baxi, William R. Brugge Gastrointestinal Endoscopy.2024; 100(6): 1090. CrossRef
Short‐term morbidity and mortality after right hemicolectomy: an update of national performance in the Netherlands J. M. L. Sijmons, A. A. J. Grüter, B. R. Toorenvliet, R. A. E. M. Tollenaar, J. W. T. Dekker, P. J. Tanis, J. B. Tuynman Colorectal Disease.2024; 26(11): 1983. CrossRef
Efficacy of Oral Sulfate Tablet and 2 L-Polyethylene Glycol With Ascorbic Acid for Bowel Preparation: A Prospective Randomized KASID Multicenter Trial Yunho Jung, Hyun Gun Kim, Dong-Hoon Yang, Hyoun Woo Kang, Jae Jun Park, Dong Hoon Baek, Jaeyoung Chun, Tae-Geun Gweon, Hyeon Jeong Goong, Min Seob Kwak, Hyun Jung Lee, Soo-Kyung Park, Jong Hoon Lee Journal of Korean Medical Science.2024;[Epub] CrossRef
Olfactomedin 4 produces dysplasia but suppresses metastasis of colon cancer Hyun Woo Ma, Jung Min Kim, Da Hye Kim, I Seul Park, Ji Hyung Kim, Ki Cheong Park, Dong Hyuk Seo, Jae Hyeon Kim, Xiumei Che, Tae Il Kim, Jae Hee Cheon, Seung Won Kim Cancer Gene Therapy.2023; 30(5): 694. CrossRef
Past, present, and future of Intestinal Research Jae Hee Cheon Intestinal Research.2023; 21(1): 1. CrossRef
Chasm between Public Perceptions and Epidemiological Data on Colorectal Cancer Su Bee Park, Min Seob Kwak, Jin Young Yoon, Jae Myung Cha Gut and Liver.2023; 17(3): 449. CrossRef
Technique, sedation, and clinical outcome of endoscopic submucosal dissection for rectal tumor with involvement of dentate line: A retrospective cohort study Yoon Kyoo Noh, Jun Lee, Seong Jung Kim Saudi Journal of Gastroenterology.2023; 29(6): 365. CrossRef
Նորագույն էնդոսկոպիկ մեթոդների դերը հաստ աղու նորագոյացությունների ախտորոշման և բուժման մեջ Ն. Գ. Զալինյան, Ա. Մ. Խալաթյան, Ս. Ա. Խաչատրյան, Մ. Ա. Նալբանդյան, Տ. Է. Ստեփանյան, Գ. Ն. Թամամյան, Կ. Դ. Մանուկյան Medical Science of Armenia.2023; : 11. CrossRef
Effectiveness and Safety of Endoscopic Submucosal Dissection for Colorectal Neoplasm in Patients with High Charlson Comorbidity Index Score: A HASID Multicenter Study Dong-Hyun Kim, Yong-Wook Jung, Byung-Chul Jin, Hyung-Hoon Oh, Hyo-Yeop Song, Seong-Jung Kim, Dae-Seong Myung, Sang-Wook Kim, Jun Lee, Geom-Seog Seo, Young-Eun Joo, Hyun-Soo Kim Journal of Clinical Medicine.2023; 12(19): 6255. CrossRef
The tumor suppressive effect and apoptotic mechanism of TRAIL gene‐containing recombinant NDV in TRAIL‐resistant colorectal cancer HT‐29 cells and TRAIL‐nonresistant HCT116 cells, with each cell bearing a mouse model Bo‐Kyoung Jung, Yong Hee An, Sung Hoon Jang, Gyoungah Ryu, Saet‐byel Jung, Seonhee Kim, Cuk‐Seong Kim, Hyun Jang Cancer Medicine.2023; 12(20): 20380. CrossRef
Clinical characteristics and risk factors related to polyposis recurrence and advanced neoplasm development among patients with non-hereditary colorectal polyposis Jihun Jang, Jihye Park, Soo Jung Park, Jae Jun Park, Jae Hee Cheon, Tae Il Kim Intestinal Research.2023; 21(4): 510. CrossRef
Summary and comparison of recently updated post-polypectomy surveillance guidelines Yoon Suk Jung Intestinal Research.2023; 21(4): 443. CrossRef
Wide-field endoscope accessory for multiplexed fluorescence imaging Gaoming Li, Miki Lee, Tse-Shao Chang, Joonyoung Yu, Haijun Li, Xiyu Duan, Xiaoli Wu, Sangeeta Jaiswal, Shuo Feng, Kenn R. Oldham, Thomas D. Wang Scientific Reports.2023;[Epub] CrossRef
Endoscopic characterization of neoplastic and non-neoplastic lesions in inflammatory bowel disease: systematic review in the era of advanced endoscopic imaging Andrea Cassinotti, Marco Parravicini, Thomas P. Chapman, Marco Balzarini, Lorenzo Canova, Simone Segato, Valentina Zadro, Simon Travis, Sergio Segato Therapeutic Advances in Gastroenterology.2023;[Epub] CrossRef
Prediction of disease recurrence or residual disease after primary endoscopic resection of pT1 colorectal cancer—results from a large nationwide Danish study Ilze Ose, Katarina Levic, Lau Caspar Thygesen, Orhan Bulut, Thue Bisgaard, Ismail Gögenur, Tine Plato Kuhlmann International Journal of Colorectal Disease.2023;[Epub] CrossRef
Inflammatory bowel disease (IBD), primarily Crohn’s disease and ulcerative colitis, had been widely recognized to affect the Western population. However, the notable rise in prevalence of IBD in Asia, including Singapore, had garnered much attention to the causal role of the shift in trend, and more importantly, effective and safe management of the conditions of these groups of patients in terms of therapy, healthcare economics as well as patient well-being. This review presents a summary of the current landscape of IBD in Singapore, and discuss on areas that can be explored to improve and better understand the local condition, as prevalence continues to grow.
Citations
Citations to this article as recorded by
Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition Filiz Akyüz, Yoon Kyo An, Jakob Begun, Satimai Aniwan, Huu Hoang Bui, Webber Chan, Chang Hwan Choi, Nazeer Chopdat, Susan J Connor, Devendra Desai, Emma Flanagan, Taku Kobayashi, Allen Yu-Hung Lai, Rupert W Leong, Alex Hwong-Ruey Leow, Wai Keung Leung, Ju Intestinal Research.2025; 23(1): 37. CrossRef
Ocular extraintestinal manifestations and treatments in patients with inflammatory bowel disease Mariana Rodriguez Duran, Ghazala A. Datoo O’Keefe Frontiers in Ophthalmology.2024;[Epub] CrossRef
Association of immune-mediated inflammatory diseases with depression and anxiety in patients with type 2 diabetes: A nationwide population-based study Oh Chan Kwon, Yuna Kim, Jaeyoung Chun, Kyungdo Han, Min-Chan Park, Ryul Kim, Jie-Hyun Kim, Young Hoon Youn, Hyojin Park Frontiers in Medicine.2023;[Epub] CrossRef
Treatment of primary sclerosing cholangitis combined with inflammatory bowel disease You Sun Kim, Edward H. Hurley, Yoojeong Park, Sungjin Ko Intestinal Research.2023; 21(4): 420. CrossRef
Evolving Trends and Burden of Inflammatory Bowel Disease in Asia, 1990–2019: A Comprehensive Analysis Based on the Global Burden of Disease Study Xuejie Chen, Xin Xiang, Weitong Xia, Xindi Li, Sidan Wang, Shuyu Ye, Li Tian, Lian Zhao, Feiyan Ai, Zhaohua Shen, Kai Nie, Minzi Deng, Xiaoyan Wang Journal of Epidemiology and Global Health.2023; 13(4): 725. CrossRef
Is primary sclerosing cholangitis with inflammatory bowel disease different between patients in the East and West? Yong Eun Park Intestinal Research.2022; 20(2): 157. CrossRef
Vaccination strategies for Korean patients with inflammatory bowel disease Yoo Jin Lee, Eun Soo Kim The Korean Journal of Internal Medicine.2022; 37(5): 920. CrossRef
Clinical Characteristics of Korean Patients with Elderly-Onset Crohn’s Disease: Results from the Prospective CONNECT Study You Sun Kim, Min Jeong Na, Byong Duk Ye, Jae Hee Cheon, Jong Pil Im, Joo Sung Kim Gut and Liver.2022; 16(6): 995. CrossRef
The timing of colonoscopy in patients with active ulcerative colitis (UC) lacks coherence. The published guidelines and recommendations advocate time-bound colonoscopy in patients with active UC to assess for mucosal healing. However, the practice of performing colonoscopies at fixed time frames lacks reasoning. The time to achieve mucosal healing in UC is not uniform across the patient populations and is influenced by the disease severity and efficacy and time to therapeutic response of the drugs being used. Additionally, with the availability of sensitive noninvasive inflammatory biomarkers such as fecal calprotectin, that parallel the disease activity and correlate with mucosal healing, the notion of performing colonoscopy at fixed intervals sounds unjustifiable. The authors express their view that a response-guided colonoscopy (driven by normalization of clinical symptoms and inflammatory biomarkers), rather than a time-bound colonoscopy, would be more logical, apart from being cost-effective and patient-friendly.
Citations
Citations to this article as recorded by
Comments on Oral Sulfate Solution Is as Effective as Polyethylene Glycol with Ascorbic Acid in a Split Method for Bowel Preparation in Patients with Inactive Ulcerative Colitis: A Randomized, Multicenter, and Single-Blind Clinical Trial Ji Eun Kim Gut and Liver.2024; 18(1): 192. CrossRef
Ischemia-modified albumin: a novel blood marker of endoscopic mucosal healing in inflammatory bowel disease Seung Bum Lee, Hyun-Ki Kim, Sang Hyuk Park, Ji-Hun Lim, Sang Hyoung Park Intestinal Research.2024; 22(1): 75. CrossRef
A novel serum biomarker of endoscopic mucosal healing in inflammatory bowel disease Hyoun Woo Kang Intestinal Research.2024; 22(1): 3. CrossRef
Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023 Hsu-Heng Yen, Jia-Feng Wu, Horng-Yuan Wang, Ting-An Chang, Chung-Hsin Chang, Chen-Wang Chang, Te-Hsin Chao, Jen-Wei Chou, Yenn-Hwei Chou, Chiao-Hsiung Chuang, Wen-Hung Hsu, Tzu-Chi Hsu, Tien-Yu Huang, Tsung-I Hung, Puo-Hsien Le, Chun-Che Lin, Chun-Chi Lin Intestinal Research.2024; 22(3): 213. CrossRef
Histologic improvement predicts endoscopic remission in patients with ulcerative colitis Ji Eun Kim, Minjee Kim, Min-Ji Kim, Eun Ran Kim, Sung Noh Hong, Dong Kyung Chang, Sang Yun Ha, Young-Ho Kim Scientific Reports.2024;[Epub] CrossRef
Practical management of mild-to-moderate ulcerative colitis: an international expert consensus Ferdinando D’Amico, Fernando Magro, Axel Dignass, Sameer Al Awadhi, Ana Gutierrez Casbas, Natália Sousa Freitas Queiroz, Grażyna Rydzewska, Byong Duk Ye, Zhihua Ran, Ailsa Hart, Vipul Jairath, Gionata Fiorino, Laurent Peyrin-Biroulet, Silvio Danese Expert Review of Gastroenterology & Hepatology.2024; 18(8): 421. CrossRef
Predictive Value of PHRI for Recurrence within One Year after UC Treatment: A Retrospective Study Kun Zhang, Jianlan Xie, Jianmin Zhao, Mei Jia British Journal of Hospital Medicine.2024; : 1. CrossRef
Molecular Activity of Inflammation and Epithelial-Mesenchymal Transition in the Microenvironment of Ulcerative Colitis Yu Kyung Jun, Nayoung Kim, Hyuk Yoon, Ji Hyun Park, Hyung Kyung Kim, Yonghoon Choi, Ji Ae Lee, Cheol Min Shin, Young Soo Park, Dong Ho Lee Gut and Liver.2024; 18(6): 1037. CrossRef
Comparison of Two Types of 1-L Polyethylene Glycol-ascorbic Acid as Colonoscopic Bowel Preparation: A Prospective Randomized Study Suh Hyun Choi, Won Eui Yoon, Seung Hyuk Kim, Hee Jun Myung, Seo Hyun Kim, Soon Oh So, Se Hun Kim, Hyun Mi Lee, Yeoun Jung Oh, Jeong Seop Moon, Tae Yeong Park, You Sun Kim The Korean Journal of Gastroenterology.2022; 80(2): 85. CrossRef
Anthony Buisson, Lisa Cannon, Konstantin Umanskiy, Roger D. Hurst, Neil H. Hyman, Atsushi Sakuraba, Joel Pekow, Sushila Dalal, Russell D. Cohen, Bruno Pereira, David T. Rubin
Intest Res 2022;20(3):303-312. Published online August 4, 2021
Background/Aims We assessed the effectiveness of anti-TNF agents and its associated factors to prevent endoscopic and clinical postoperative recurrence (POR) in Crohn’s disease (CD).
Methods From a prospectively-maintained database, we retrieved 316 CD patients who underwent intestinal resection (2011–2017). Endoscopic (Rutgeerts index ≥ i2 at 6 months) and clinical (recurrence of symptoms leading to hospitalization or therapeutic escalation) POR were assessed.
Results In 117 anti-TNF-naïve patients, anti-TNF therapy was more effective than immunosuppressive agents (odds ratio [OR], 8.8; 95% confidence interval [CI], 1.8–43.9; P= 0.008) and no medication/5-aminosalicylates (OR, 5.2; 95% CI, 1.0–27.9; P= 0.05) to prevent endoscopic POR. In 199 patients exposed to anti-TNF prior to the surgery, combination with anti-TNF and immunosuppressive agents was more effective than anti-TNF monotherapy (OR, 2.32; 95% CI, 1.02–5.31; P= 0.046) to prevent endoscopic POR. Primary failure to anti-TNF agent prior to surgery was predictive of anti-TNF failure to prevent endoscopic POR (OR, 2.41; 95% CI, 1.10–5.32; P= 0.03). When endoscopic POR despite anti-TNF prophylactic medication (n = 55), optimizing anti-TNF and adding an immunosuppressive drug was the most effective option to prevent clinical POR (hazard ratio, 7.38; 95% CI, 1.54–35.30; P= 0.012). Anti-TNF therapy was the best option to prevent clinical POR (hazard ratio, 3.10; 95% CI, 1.09–8.83; P= 0.034) in patients with endoscopic POR who did not receive any biologic to prevent endoscopic POR (n = 55).
Conclusions Anti-TNF was the most effective medication to prevent endoscopic and clinical POR. Combination with anti-TNF and immunosuppressive agents should be considered in patients previously exposed to anti-TNF.
Citations
Citations to this article as recorded by
Impact of age at diagnosis on long‐term prognosis in patients with intestinal Behçet's disease Ji Young Chang, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Hee Cheon, Jihye Park Journal of Gastroenterology and Hepatology.2024; 39(3): 519. CrossRef
Postoperative small bowel Crohn's disease: how to diagnose, manage and treat Chak Lam Ip, Ray Boyapati, Rahul Kalla Current Opinion in Gastroenterology.2024; 40(3): 209. CrossRef
Stapled End-To-Side Ileocolic Anastomosis in Crohn’s Disease: Old Dog, Reliable Tricks? A Retrospective Two-Center Cohort Study Volkan Doğru, Jean H. Ashburn, Umut Akova, Alton G. Sutter, Eren Esen, Emily M. Gardner, Andre da Luz Moreira, Arman Erkan, John Kirat, Michael J. Grieco, Feza H. Remzi Annals of Surgery Open.2024; 5(1): e374. CrossRef
Clinical Significance of Prognostic Nutrition Index in Patients with Crohn’s Disease after Primary Bowel Resection Hyeon Woo Bae, Yong Joon Lee, Min Young Park, Seung Yoon Yang, Yoon Dae Han, Min Soo Cho, Hyuk Hur, Kang Young Lee, Jae Hee Cheon, Joseph C. Carmichael, Byung Soh Min Yonsei Medical Journal.2024; 65(7): 380. CrossRef
How Reliable Is Endoscopic Scoring of Postoperative Recurrence in Crohn Disease?: A Systematic Review and Meta-Analysis Eline M. L. van der Does de Willebois, Vittoria Bellato, Marjolijn Duijvestein, Susan van Dieren, Silvio Danese, Pierpaolo Sileri, Christianne J. Buskens, Andrea Vignali, Willem A. Bemelman Annals of Surgery Open.2024; 5(1): e397. CrossRef
Systematic review: Patient‐related, microbial, surgical, and histopathological risk factors for endoscopic post‐operative recurrence in patients with Crohn's disease Michiel T. J. Bak, Karlijn Demers, Nassim Hammoudi, Matthieu Allez, Mark S. Silverberg, Gwenny M. Fuhler, Kaushal Parikh, Marieke J. Pierik, Laurents P. S. Stassen, C. Janneke van der Woude, Michail Doukas, Oddeke van Ruler, Annemarie C. de Vries Alimentary Pharmacology & Therapeutics.2024; 60(3): 310. CrossRef
Common Mistakes in Managing Patients with Inflammatory Bowel Disease Javier P. Gisbert, María Chaparro Journal of Clinical Medicine.2024; 13(16): 4795. CrossRef
Preventing Recurrence of Crohn’s Disease Post-Ileocaecal Surgery in Paediatric Patients: A Therapy Guide Based on Systematic Review of the Evidence Jiri Bronsky, Kristyna Zarubova, Michal Kubat, Vojtech Dotlacil Pediatric Drugs.2024; 26(6): 659. CrossRef
Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn’s Disease Javier P. Gisbert, María Chaparro Drugs.2023; 83(13): 1179. CrossRef
Prevention of postoperative recurrence in Crohn’s disease: the never-ending story Jung-Bin Park, Sang Hyoung Park Intestinal Research.2022; 20(3): 279. CrossRef
Timing of individualized surgical intervention in Crohn’s disease Kai Xia, Ren-Yuan Gao, Xiao-Cai Wu, Lu Yin, Chun-Qiu Chen World Journal of Gastrointestinal Surgery.2022; 14(12): 1320. CrossRef
Background/Aims Restorative proctocolectomy (RPC) with ileal pouch-anal anastomosis and handsewn anastomosis for ulcerative colitis requires pulling down of the ileal pouch into the pelvis, which can be technically challenging. We examined risk factors for the pouch not reaching the anus.
Methods Clinical records of 62 consecutive patients who were scheduled to undergo RPC with handsewn anastomosis at the University of Tokyo Hospital during 1989–2019 were reviewed. Risk factors for non-reaching were analyzed in patients in whom hand sewing was abandoned for stapled anastomosis because of nonreaching. Risk factors for non-reaching in laparoscopic RPC were separately analyzed. Anatomical indicators obtained from presurgical computed tomography (CT) were also evaluated.
Results Thirty-seven of 62 cases underwent laparoscopic procedures. In 6 cases (9.7%), handsewn anastomosis was changed to stapled anastomosis because of non-reaching. Male sex and a laparoscopic approach were independent risk factors of non-reaching. Distance between the terminal of the superior mesenteric artery (SMA) ileal branch and the anus > 11 cm was a risk factor for non-reaching.
Conclusions Laparoscopic RPC with handsewn anastomosis may limit extension and induction of the ileal pouch into the anus. Preoperative CT measurement from the terminal SMA to the anus may be useful for predicting non-reaching.
Citations
Citations to this article as recorded by
Temporary loop end ileostomy reduces the risk of stoma outlet obstruction: a comparative clinical study in patients undergoing restorative proctocolectomy and ileal pouch-anal anastomosis Takayuki Ogino, Yuki Sekido, Tsunekazu Mizushima, Makoto Fujii, Ryota Mori, Mitsunobu Takeda, Tsuyoshi Hata, Atsushi Hamabe, Norikatsu Miyoshi, Mamoru Uemura, Yuichiro Doki, Hidetoshi Eguchi Surgery Today.2024;[Epub] CrossRef
Preoperative Simulation of Ileal Pouch–Anal Anastomosis in Patients With Ulcerative Colitis Using a 3-Dimensional Printed Model Shota Yokose, Koji Murono, Hiroaki Nozawa, Kazuhito Sasaki, Shigenobu Emoto, Hiroyuki Matsuzaki, Yuichiro Yokoyama, Shinya Abe, Yuzo Nagai, Yuichiro Yoshioka, Takahide Shinagawa, Hirofumi Sonoda, Shin Murai, Koichi Komatsu, Soichiro Ishihara Inflammatory Bowel Diseases.2023; 29(12): 1865. CrossRef
Preoperative Computed Tomography Indices Predict Non-reach Prior to Ileal Pouch-Anal Anastomosis Evan D. Adams, Charlotte A Lansky, Cindy E. Kallman, Karen N. Zaghiyan, Phillip R. Fleshner Diseases of the Colon & Rectum.2023;[Epub] CrossRef
Laparoscopic vs open restorative proctectomy after total abdominal colectomy for ulcerative colitis or familial adenomatous polyposis Hiroaki Nozawa, Keisuke Hata, Kazuhito Sasaki, Koji Murono, Kazushige Kawai, Shigenobu Emoto, Soichiro Ishihara Langenbeck's Archives of Surgery.2022; 407(4): 1605. CrossRef
Recent Advance in the Management of Dysplasia in the Ulcerative Colitis Dong-Hoon Yang Journal of Digestive Cancer Reports.2021; 9(2): 50. CrossRef
Background/Aims Nutritional status influences quality of life among patients with inflammatory bowel disease (IBD), although there is no clear method to evaluate nutritional status in this setting. Therefore, this study examined whether bioelectrical impedance analysis (BIA) could be used to evaluate the nutritional status of patients with IBD.
Methods We retrospectively analyzed data from 139 Korean patients with IBD who were treated between November 2018 and November 2019. Patients were categorized as having active or inactive IBD based on the Harvey-Bradshaw index (a score of ≥5 indicates active Crohn’s disease) and the partial Mayo scoring index (a score of ≥2 indicates active ulcerative colitis). BIA results and serum nutritional markers were analyzed according to disease activity.
Results The mean patient age was 45.11±17.71 years. The study included 47 patients with ulcerative colitis and 92 patients with Crohn’s disease. Relative to the group with active disease (n=72), the group with inactive disease (n=67) had significantly higher values for hemoglobin (P<0.001), total protein (P<0.001), and albumin (P<0.001). Furthermore, the group with inactive disease had higher BIA values for body moisture (P=0.047), muscle mass (P=0.046), skeletal muscle mass (P=0.042), body mass index (P=0.027), and mineral content (P=0.034). Moreover, the serum nutritional markers were positively correlated with the BIA results.
Conclusions Nutritional markers evaluated using BIA were correlated with serum nutritional markers and inversely correlated with disease activity. Therefore, we suggest that BIA may be a useful tool that can help existing nutritional tests monitor the nutritional status of IBD patients.
Citations
Citations to this article as recorded by
Comparison of body composition change, measured with bioelectrical impedance analysis, between singleton and twin pregnancy: A prospective cohort study Bo Young Choi, Sae Yeon Jung, Hee Kyeong Lee, Min Jung Lee, Hyeon Ji Kim, Jee Yoon Park, Kyung Joon Oh European Journal of Obstetrics & Gynecology and Reproductive Biology.2025; 306: 154. CrossRef
BODY FAT COMPOSITION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES: A COMPARATIVE STUDY BETWEEN SKINFOLDS AND ULTRASONOGRAPHY Isadora Sayuri Macedo TUMA, Maria Paula Carlin CAMBI, Thyago Proença de MORAES, Daniéla Oliveira MAGRO, Paulo Gustavo KOTZE Arquivos de Gastroenterologia.2024;[Epub] CrossRef
Navigating the Intersection: Sarcopenia and Sarcopenic Obesity in Inflammatory Bowel Disease Valentin Calvez, Guia Becherucci, Carlo Covello, Giulia Piccirilli, Irene Mignini, Giorgio Esposto, Lucrezia Laterza, Maria Elena Ainora, Franco Scaldaferri, Antonio Gasbarrini, Maria Assunta Zocco Biomedicines.2024; 12(6): 1218. CrossRef
Association between inflammatory bowel disease and osteoporosis in European and East Asian populations: exploring causality, mediation by nutritional status, and shared genetic architecture Jian Kang, Xize Wu, Yue Li, Shuangli Zhao, Shixuan Wang, Dongdong Yu Frontiers in Immunology.2024;[Epub] CrossRef
Micronutrient Deficiency and Muscular Status in Inflammatory Bowel Disease Joonhee Han, Hyun Joo Song, Min Sook Kang, Hogyung Jun, Heung Up Kim, Ki Soo Kang, Donghyoun Lee Nutrients.2024; 16(21): 3763. CrossRef
Evaluation of Nutritional Characteristics Reveals Similar Prevalence of Malnutrition in Patients with Ulcerative Colitis and Crohn’s Disease Arshdeep Singh, Vandana Midha, Ramit Mahajan, Shruti Verma, Chandan Kakkar, Jasmine Grover, Dharmatma Singh, Ramandeep Kaur, Abhishek Masih, Namita Bansal, Catherine Wall, Ajit Sood Digestive Diseases and Sciences.2023; 68(2): 580. CrossRef
Response to Ustekinumab Therapy Is Associated with an Improvement of Nutritional Status in Patients with Crohn’s Disease Lorenzo Bertani, Claudia D’Alessandro, Marco Fornili, Francesca Coppini, Federico Zanzi, Luca Carmisciano, Francesca Geri, Giovanni Baiano Svizzero, Emma Maria Rosi, Alice De Bernardi, Linda Ceccarelli, Maria Gloria Mumolo, Laura Baglietto, Massimo Bellin Journal of Clinical Medicine.2023; 12(19): 6118. CrossRef
Clinical Implications of Dietary Probiotic Supplement (Associated with L-Glutamine and Biotin) in Ulcerative Colitis Patients’ Body Composition and Quality of Life Flavia Maria Pavel, Simona Gabriela Bungau, Delia Mirela Tit, Timea Claudia Ghitea, Ruxandra Cristina Marin, Andrei-Flavius Radu, Radu Dumitru Moleriu, Tiberia Ilias, Cristian Bustea, Cosmin Mihai Vesa Nutrients.2023; 15(24): 5049. CrossRef
Background/Aims Golimumab (GLM) is an anti-tumor necrosis factor-α drug approved for treating moderate-to-severe active ulcerative colitis (UC). A 52-week post-marketing surveillance (PMS) was initiated to evaluate its safety and effectiveness in patients with UC in Japan. We present an interim report of the ongoing PMS.
Methods Patients received 200 mg of subcutaneous GLM at week 0, 100 mg at week 2, and 100 mg 4 weekly thereafter. The safety analysis set included 392 patients with UC, and the effectiveness analysis set 387 patients. Safety and effectiveness were assessed at week 6.
Results Adverse drug reactions (ADRs) were reported in 8.2% (32/392) and serious ADRs in 4.6% (18/392). The most frequent ADRs were infection and infestation (3.3%), with herpes zoster being the most common. ADRs were significantly higher in patients with concomitant corticosteroid use (odds ratio [OR], 3.45; 95% confidence interval [CI], 1.40–9.68). No significant difference in ADR incidence was observed between patients aged ≥65 and <65 years (OR, 1.23; 95% CI, 0.35–3.47). Six-week effectiveness of GLM was confirmed by a decrease in the partial Mayo score (–2.3; 95% CI, –2.6 to –2.1) and C-reactive protein levels (–0.64; 95% CI, –0.92 to –0.36), including in the biologics-experienced population.
Conclusions The safety and effectiveness of GLM at week 6 in a real-world setting were demonstrated in patients with UC in Japan. ADR patterns were consistent with previous reports with no new safety signals. Concomitant corticosteroid use may be associated with increased ADR incidence. The final results of the ongoing PMS are necessary for further evaluation.
Citations
Citations to this article as recorded by
Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: Evidence from a systematic literature review Peter M. Irving, Peter Hur, Raju Gautam, Xiang Guo, Severine Vermeire Journal of Managed Care & Specialty Pharmacy.2024; 30(9): 1026. CrossRef
Reviewing not Homer’s Iliad, but “Kai Bao Ben Cao”: indigo dye—the past, present, and future Yusuke Yoshimatsu, Tomohisa Sujino, Takanori Kanai Intestinal Research.2023; 21(2): 174. CrossRef
Golimumab for Ulcerative Colitis: One More Option to SAVE the Colon Sang Hyoung Park Crohn's & Colitis 360.2023;[Epub] CrossRef
Advancements in the Management of Moderate-to-Severe Ulcerative Colitis: A Revised 2023 Korean Treatment Guidelines Soo-Young Na The Korean Journal of Medicine.2023; 98(5): 223. CrossRef
Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review Ji Young Chang, Jae Hee Cheon Precision and Future Medicine.2021; 5(4): 151. CrossRef
Background/Aims Proinflammatory cytokines released from adipocytes can influence the development, progression, and treatment of inflammatory bowel disease (IBD), and may be associated with worse clinical outcomes.
Methods For 2016–2018, we analyzed data from the Nationwide Inpatient Sample to identify adult (≥18 years) hospitalizations with a primary discharge diagnosis of IBD. The study sample was divided based on the presence or absence of obesity. The primary outcomes included inpatient mortality, while the secondary outcomes consisted of system-based complications and disease implications on the United States healthcare system.
Results We identified 282,005 hospitalizations of IBD from 2016 to 2018. Of these hospitalizations, 26,465 (9.4%) had a secondary diagnosis of obesity while 255,540 (90.6%) served as controls. IBD hospitalizations with obesity had a higher mean age (47.9 years vs. 45.2 years, P<0.001), middle age (range, 40–65 years) predominance (37.7% vs. 28.9%, P<0.001), female predominance (64.1% vs. 52.5%, P<0.001) and higher proportion of patients with comorbidities compared to the non-obese cohort. White predominance was observed in both subgroups. No difference in the odds of inpatient mortality was noted between the 2 subgroups; however, IBD hospitalizations with obesity had higher mean total hospital charge ($50,126 vs. $45,001, P<0.001), longer length of stay (5.5 days vs. 4.9 days, P<0.001) and higher proportion of complications compared to the non-obese cohort.
Conclusions Obese IBD hospitalizations had higher length of stay, total hospital charge, and complications compared to the non-obese cohort.
Citations
Citations to this article as recorded by
Obesity and Chronic Inflammation: Implications for Rheumatoid Arthritis, Spondyloarthritis, and Ulcerative Colitis Ada Corrado, Ilaria Guadagni, Giovanna Picarelli, Angela Variola Immunity, Inflammation and Disease.2025;[Epub] CrossRef
Recomendaciones sobre el manejo de la obesidad grave en pacientes con enfermedad inflamatoria intestinal del Grupo Español de Trabajo en Enfermedad Inflamatoria Intestinal (GETECCU), Sociedad Española de Obesidad (SEEDO), Asociación Española de Cirugía (A Eugeni Domènech, Andreea Ciudin, José María Balibrea, Eduard Espinet-Coll, Fiorella Cañete, Lilliam Flores, Manuel Ferrer-Márquez, Román Turró, Alejandro Hernández-Camba, Yamile Zabana, Ana Gutiérrez, José María Balibrea, Manuel Barreiro-de Acosta, Javier Gastroenterología y Hepatología.2024; 47(8): 906. CrossRef
The Rising Epidemic of Obesity in Patients with Inflammatory Bowel Disease Jellyana Peraza, Erin Abbott, Mark Shneyderman, Asher Kornbluth, Maitreyi Raman, Stephanie Gold Current Treatment Options in Gastroenterology.2024; 22(3): 134. CrossRef
Recommendations on the management of severe obesity in patients with inflammatory bowel disease of the Spanish Group on Crohn’s Disease and Ulcerative Colitis (GETECCU), Spanish Society of Obesity (SEEDO), Spanish Association of Surgery (AEC) and Spanish Eugeni Domènech, Andreea Ciudin, José María Balibrea, Eduard Espinet-Coll, Fiorella Cañete, Lilliam Flores, Manuel Ferrer-Márquez, Román Turró, Alejandro Hernández-Camba, Yamile Zabana, Ana Gutiérrez, José María Balibrea, Manuel Barreiro-de Acosta, Javier Gastroenterología y Hepatología (English Edition).2024; 47(8): 906. CrossRef
Body Mass Index Profile of Adult Patients with Inflammatory Bowel Disease in a Multicenter Study in Northeastern Brazil Jones Lima, Carlos Brito, Lívia Celani, Marcelo Vicente Araújo, Maurilio Lucena, Graciana Vasconcelos, Gustavo Lima, Fernando Nóbrega, George Diniz, Norma Lucena-Silva, Regiane Maio, Valéria Martinelli Clinical and Experimental Gastroenterology.2023; Volume 16: 213. CrossRef
Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study Seung Yong Shin, Soo Jung Park, Young Kim, Jong Pil Im, Hyo Jong Kim, Kang-Moon Lee, Ji Won Kim, Sung-Ae Jung, Jun Lee, Sang-Bum Kang, Sung Jae Shin, Eun Sun Kim, You Sun Kim, Tae Oh Kim, Hyun-Soo Kim, Dong Il Park, Hyung Kil Kim, Eun Soo Kim, Young-Ho Ki Intestinal Research.2022; 20(3): 350. CrossRef
Seung Yong Shin, Soo Jung Park, Young Kim, Jong Pil Im, Hyo Jong Kim, Kang-Moon Lee, Ji Won Kim, Sung-Ae Jung, Jun Lee, Sang-Bum Kang, Sung Jae Shin, Eun Sun Kim, You Sun Kim, Tae Oh Kim, Hyun-Soo Kim, Dong Il Park, Hyung Kil Kim, Eun Soo Kim, Young-Ho Kim, Do Hyun Kim, Dennis Teng, Jong-Hwa Kim, Wonyong Kim, Chang Hwan Choi, on behalf of the IBD Research Group of the Korean Association for the Study of Intestinal Diseases
Intest Res 2022;20(3):350-360. Published online July 23, 2021
Background/Aims This study assessed the efficacy and safety of adalimumab (ADA) and explored predictors of response in Korean patients with ulcerative colitis (UC).
Methods A prospective, observational, multicenter study was conducted over 56 weeks in adult patients with moderately to severely active UC who received ADA. Clinical response, remission, and mucosal healing were assessed using the Mayo score.
Results A total of 146 patients were enrolled from 17 academic hospitals. Clinical response rates were 52.1% and 37.7% and clinical remission rates were 24.0% and 22.0% at weeks 8 and 56, respectively. Mucosal healing rates were 39.0% and 30.1% at weeks 8 and 56, respectively. Prior use of anti-tumor necrosis factor-α (anti-TNF-α) did not affect clinical and endoscopic responses. The ADA drug level was significantly higher in patients with better outcomes at week 8 (P<0.05). In patients with lower endoscopic activity, higher body mass index, and higher serum albumin levels at baseline, the clinical response rate was higher at week 8. In patients with lower Mayo scores and C-reactive protein levels, clinical responses, and mucosal healing at week 8, the clinical response rate was higher at week 56. Serious adverse drug reactions were identified in 2.8% of patients.
Conclusions ADA is effective and safe for induction and maintenance in Korean patients with UC, regardless of prior anti-TNF-α therapy. The ADA drug level is associated with the efficacy of induction therapy. Patients with better short-term outcomes were predictive of those with an improved long-term response.
Citations
Citations to this article as recorded by
Prospective Observational Evaluation of the Time-Dependency of Adalimumab Immunogenicity and Drug Concentration in Ulcerative Colitis Patients: the POETIC II Study Sivan Harnik, Chaya M Abitbol, Ola Haj Natour, Miri Yavzori, Ella Fudim, Orit Picard, Timna Naftali, Efrat Broide, Ayal Hirsch, Limor Selinger, Eyal Shachar, Doron Yablecovitch, Ahmad Albshesh, Daniel Coscas, Uri Kopylov, Rami Eliakim, Shomron Ben-Horin, Journal of Crohn's and Colitis.2024; 18(3): 341. CrossRef
Rapidly achieving clinical remission in ulcerative colitis indicates better endoscopic and histological outcomes Rirong Chen, Yizhe Tie, Yongle Huang, Xi Zhang, Zhirong Zeng, Minhu Chen, Li Li, Shenghong Zhang United European Gastroenterology Journal.2024; 12(4): 459. CrossRef
Effectiveness of adalimumab in severe ulcerative colitis: A systematic review and a meta‐analysis Saleh Azadbakht, Masomeh Seighali, Salehe Azadbakht, Morteza Azadbakht Health Science Reports.2024;[Epub] CrossRef
Dynamic changes in the gut microbiota composition during adalimumab therapy in patients with ulcerative colitis: implications for treatment response prediction and therapeutic targets Han Na Oh, Seung Yong Shin, Jong-Hwa Kim, Jihye Baek, Hyo Jong Kim, Kang-Moon Lee, Soo Jung Park, Seok-Young Kim, Hyung-Kyoon Choi, Wonyong Kim, Woo Jun Sul, Chang Hwan Choi Gut Pathogens.2024;[Epub] CrossRef
Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: Evidence from a systematic literature review Peter M. Irving, Peter Hur, Raju Gautam, Xiang Guo, Severine Vermeire Journal of Managed Care & Specialty Pharmacy.2024; 30(9): 1026. CrossRef
Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis Soo-Young Na, Chang Hwan Choi, Eun Mi Song, Ki Bae Bang, Sang Hyoung Park, Eun Soo Kim, Jae Jun Park, Bora Keum, Chang Kyun Lee, Bo-In Lee, Seung-Bum Ryoo, Seong-Joon Koh, Miyoung Choi, Joo Sung Kim Intestinal Research.2023; 21(1): 61. CrossRef
Changes in fecal metabolic and lipidomic features by anti-TNF treatment and prediction of clinical remission in patients with ulcerative colitis Seok-Young Kim, Seung Yong Shin, Soo Jung Park, Jong Pil Im, Hyo Jong Kim, Kang-Moon Lee, Ji Won Kim, Sung-Ae Jung, Jun Lee, Sang-Bum Kang, Sung Jae Shin, Eun Sun Kim, You Sun Kim, Tae Oh Kim, Hyun-Soo Kim, Dong Il Park, Hyung Kil Kim, Eun Soo Kim, Young- Therapeutic Advances in Gastroenterology.2023;[Epub] CrossRef
Reviewing not Homer’s Iliad, but “Kai Bao Ben Cao”: indigo dye—the past, present, and future Yusuke Yoshimatsu, Tomohisa Sujino, Takanori Kanai Intestinal Research.2023; 21(2): 174. CrossRef
Precision medicine and drug optimization in adult inflammatory bowel disease patients Sophie Vieujean, Edouard Louis Therapeutic Advances in Gastroenterology.2023;[Epub] CrossRef
Real-world effectiveness and safety of adalimumab in Korean patients with intestinal Behcet’s disease: a Korean Association for the Study of Intestinal Diseases (KASID) multicenter study Seung Bum Lee, Hee Seung Hong, Chang Kyun Lee, Bo-In Lee, Sol Kim, Seong-Joon Koh, Hosun Yu, Jung-Bin Park, Sung Wook Hwang, Byong Duk Ye, Suk-Kyun Yang, Sang Hyoung Park The Korean Journal of Internal Medicine.2023; 38(5): 661. CrossRef
Advancements in the Management of Moderate-to-Severe Ulcerative Colitis: A Revised 2023 Korean Treatment Guidelines Soo-Young Na The Korean Journal of Medicine.2023; 98(5): 223. CrossRef
Prediction of Clinical Remission with Adalimumab Therapy in Patients with Ulcerative Colitis by Fourier Transform–Infrared Spectroscopy Coupled with Machine Learning Algorithms Seok-Young Kim, Seung Yong Shin, Maham Saeed, Ji Eun Ryu, Jung-Seop Kim, Junyoung Ahn, Youngmi Jung, Jung Min Moon, Chang Hwan Choi, Hyung-Kyoon Choi Metabolites.2023; 14(1): 2. CrossRef
Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program Marla C Dubinsky, Fernando Magro, Flavio Steinwurz, David P Hudesman, Jami A Kinnucan, Ryan C Ungaro, Markus F Neurath, Nicole Kulisek, Jerome Paulissen, Chinyu Su, Dario Ponce de Leon, Miguel Regueiro Inflammatory Bowel Diseases.2022;[Epub] CrossRef
Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Multicenter, Prospective, Postmarketing Surveillance Study Jongwook Yu, Soo Jung Park, Hyung Wook Kim, Yun Jeong Lim, Jihye Park, Jae Myung Cha, Byong Duk Ye, Tae Oh Kim, Hyun-Soo Kim, Hyun Seok Lee, Su Young Jung, Youngdoe Kim, Chang Hwan Choi Gut and Liver.2022; 16(5): 764. CrossRef
Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review Ji Young Chang, Jae Hee Cheon Precision and Future Medicine.2021; 5(4): 151. CrossRef
José María Paredes, Tomás Ripollés, Ángela Algarra, Rafael Diaz, Nadia Moreno, Patricia Latorre, María Jesús Martínez, Pilar Llopis, Antonio López, Eduardo Moreno-Osset
Intest Res 2022;20(3):361-369. Published online March 15, 2022
Background/Aims Tight control of inflammation and adjustment of treatment if activity persists is the current strategy for the management of Crohn’s disease (CD). The usefulness of fecal calprotectin (FC) in isolated involvement of the small intestine in CD is controversial. To assess the usefulness of FC to determine the inflammatory activity detected by intestinal ultrasonography (IUS) in ileal CD.
Methods Patients with exclusively ileal involvement CD who underwent IUS and an FC were prospectively included. Simple ultrasound index was used to determine inflammatory activity. The usual statistical tests for comparison of diagnostic techniques were used.
Results One hundred and five patients were included, IUS showed inflammatory activity in 59% of patients and complications in 18.1%. FC showed a significant correlation with IUS in the weak range (Spearman coefficient r=0.502; P<0.001); the area under the receiver operating characteristic curve was 0.79 (95% confidence interval, 0.70–0.88; P<0.001). The FC value that best reflected the activity in IUS was 100 μg/g with sensitivity, specificity, and positive and negative predictive values of 73.0%, 71.4%, 79.3% and 63.8%, respectively. There were no differences in FC concentration between patients with or without transmural complications. The addition of serum C-reactive protein to FC did not improve the ability to assess IUS activity.
Conclusions FC has a significant correlation with IUS to monitor ileal CD activity. This correlation is weak and it does not allow assessing the presence of CD complications. Both tests should be used in conjunction for tight control of ileal CD. More studies on noninvasive tests in this location are needed.
Citations
Citations to this article as recorded by
Fecal calprotectin, intestinal ultrasound, and their combination for the diagnosis of inflammatory bowel disease Serge Dubian, Clara Yzet, Franck Brazier, Thierry Yzet, Vincent Hautefeuille, Catherine Decrombecque, Quentin Bocquillon, Nicolas Richard, Anthony Buisson, Jonathan Meynier, Mathurin Fumery Clinics and Research in Hepatology and Gastroenterology.2025; 49(3): 102549. CrossRef
Novelties and Perspectives of Intestinal Ultrasound in the Personalised Management of Patients with Inflammatory Bowel Diseases—A Systematic Review Vasile-Claudiu Mihai, Liliana Gheorghe, Ioana-Irina Rezuș, Alina Ecaterina Jucan, Mihaela-Cristiana Andronic, Otilia Gavrilescu, Mihaela Dranga, Andrei-Mihai Andronic, Cristina Cijevschi Prelipcean, Ciprian Rezuș, Cătălina Mihai Diagnostics.2024; 14(8): 812. CrossRef
The intestinal ultrasound role in inflammatory bowel disease in clinical practice and a critical appraisal of the current guidelines (mini-review) Sarah El-Nakeep The Egyptian Journal of Internal Medicine.2024;[Epub] CrossRef
Intestinal Ultrasonography as an Alternative to Fecal Calprotectin to Monitor Patients with Crohn’s Disease: Experience from a Novice Sonographer Kelly Mathieu, Jérémy Junda, Régine Minet-Quinard, Dilek Coban, Marie Dodel, Bruno Pereira, Anthony Buisson Digestive Diseases and Sciences.2024; 69(9): 3402. CrossRef
Intestinal ultrasound for follow-up after 24 weeks of biological therapy in inflammatory bowel disease patients: an Egyptian center experience during the COVID-19 pandemic Sarah El-Nakeep, Ehab Nashaat, Fatma Alsherif, Mohamed Magdy Salama Egyptian Journal of Radiology and Nuclear Medicine.2024;[Epub] CrossRef
Assessing Active Bowel Inflammation in Crohn's Disease Using Intestinal Ultrasound Myung‐won You, Sung Kyoung Moon, Yong Dae Lee, Shin Ju Oh, Seong Jin Park, Chang Kyun Lee Journal of Ultrasound in Medicine.2023; 42(12): 2791. CrossRef
Standardizing Endoscopic Reporting in Patients with IBD: JEDII™ to the Rescue? Sara Massironi, Alice Laffusa, Tommaso Lorenzo Parigi, Silvio Danese Digestive Diseases and Sciences.2023; 68(12): 4287. CrossRef
Application of transabdominal ultrasound in Crohn’s disease Wei-Jie Chen, Lei-Lei Luo, Zhi-Xing Dong, Jing Wu, Xing-Xing Gu, Zhao-Lian Bian World Chinese Journal of Digestology.2022; 30(8): 364. CrossRef
Is radiological healing alone enough? ‘Can’t take my eyes off’ the mucosa Su Hyun Park, Sang Hyoung Park The Korean Journal of Internal Medicine.2022; 37(3): 551. CrossRef
Background/Aims Crosstalk between the gut microbiota and bile acid plays an important role in the pathogenesis of gastrointestinal disorders. We investigated the relationship between microbial structure and bile acid metabolism in the ileal mucosa of Crohn’s disease (CD).
Methods Twelve non-CD controls and 38 CD patients in clinical remission were enrolled. Samples were collected from the distal ileum under balloon-assisted enteroscopy. Bile acid composition was analyzed by liquid chromatography-mass spectrometry. The gut microbiota was analyzed by 16S rRNA gene sequencing.
Results The Shannon evenness index was significantly lower in endoscopically active lesions than in non-CD controls. β-Diversity, evaluated by the UniFrac metric, revealed a significant difference between the active lesions and non-CD controls (P=0.039). The relative abundance of Escherichia was significantly higher and that of Faecalibacterium and Roseburia was significantly lower in CD samples than in non-CD controls. The increased abundance of Escherichia was more prominent in active lesions than in inactive lesions. The proportion of conjugated bile acids was significantly higher in CD patients than in non-CD controls, but there was no difference in the proportion of primary or secondary bile acids. The genera Escherichia and Lactobacillus were positively correlated with the proportion of conjugated bile acids. On the other hand, Roseburia, Intestinibacter, and Faecalibacterium were negatively correlated with the proportion of conjugated bile acids.
Conclusions Mucosa-associated dysbiosis and the alteration of bile acid composition were identified in the ileum of CD patients. These may play a role in the pathophysiology of ileal lesions in CD patients.
Citations
Citations to this article as recorded by
hUCMSCs Regulate Bile Acid Metabolism to Prevent Heart Failure–Induced Intestinal Injury by Inhibiting the Activation of the STAT3/NF‐κB/MAPK Signaling Pathway via TGR5 Zetian Wang, Wei Luo, Qing Wang, Chunzheng Liu, Yanshan Gong, Baitian Li, Xuejiao Zeng, Jiaqi Lin, Zehua Su, Xin Li, Yongze Yu, Zhongmin Liu, Ling Gao, Lijun Liao Food Frontiers.2025; 6(1): 575. CrossRef
A critical review on inflammatory bowel diseases risk factors, dietary nutrients regulation and protective pathways based on gut microbiota during recent 5 years Pengkui Xia, Tao Hou, Hong Jin, Yaqi Meng, Jing Li, Fuchao Zhan, Fang Geng, Bin Li Critical Reviews in Food Science and Nutrition.2024; 64(24): 8805. CrossRef
Gut microbiota disparities between active Crohn's disease and healthy controls: A global systematic review Rupa Tharu, Geetika Malik Ahlawat, Savitesh Kushwaha, Poonam Khanna Clinical Epidemiology and Global Health.2024; 25: 101497. CrossRef
Gut microbes improve prognosis of Klebsiella pneumoniae pulmonary infection through the lung-gut axis Yuxiu Tang, Liquan Chen, Jin Yang, Suqing Zhang, Jun Jin, Yao Wei Frontiers in Cellular and Infection Microbiology.2024;[Epub] CrossRef
Integrated Analysis of Microbiome and Metabolome Reveals Disease-Specific Profiles in Inflammatory Bowel Diseases and Intestinal Behçet’s Disease Yehyun Park, Jae Bum Ahn, Da Hye Kim, I Seul Park, Mijeong Son, Ji Hyung Kim, Hyun Woo Ma, Seung Won Kim, Jae Hee Cheon International Journal of Molecular Sciences.2024; 25(12): 6697. CrossRef
Gut Bacterial Composition and Nutritional Implications in Mexican and Spanish Individuals with Inflammatory Bowel Disease Compared to Healthy Controls Ricardo García-Gamboa, Osiris Díaz-Torres, Misael Sebastián Gradilla-Hernández, Vicente Pérez-Brocal, Andrés Moya, Marisela González-Avila International Journal of Molecular Sciences.2024; 25(22): 11887. CrossRef
Bile acid–induced metabolic changes in the colon promote Enterobacteriaceae expansion and associate with dysbiosis in Crohn’s disease Ravi Holani, Haggai Bar-Yoseph, Zakhar Krekhno, Antonio Serapio-Palacios, Kyung-Mee Moon, Richard G. Stacey, Katherine A. Donald, Wanyin Deng, Brian Bressler, Armando A. Magaña, Leonard J. Foster, Michael G. Atser, James D. Johnson, Barton Finlay Science Signaling.2024;[Epub] CrossRef
Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease Seung Yong Shin, Young Kim, Won-Seok Kim, Jung Min Moon, Kang-Moon Lee, Sung-Ae Jung, Hyesook Park, Eun Young Huh, Byung Chang Kim, Soo Chan Lee, Chang Hwan Choi Intestinal Research.2023; 21(1): 148. CrossRef
Meta-Analysis Reveals Compositional and Functional Microbial Changes Associated with Osteoporosis Oluwamayowa S. Akinsuyi, Luiz F. W. Roesch, Olubukola Oluranti Babalola Microbiology Spectrum.2023;[Epub] CrossRef
Crohn’s disease: Why the ileum? Nicolas Richard, Guillaume Savoye, Mathilde Leboutte, Asma Amamou, Subrata Ghosh, Rachel Marion-Letellier World Journal of Gastroenterology.2023; 29(21): 3222. CrossRef
The Emerging Role of Raman Spectroscopy as an Omics Approach for Metabolic Profiling and Biomarker Detection toward Precision Medicine Gabriel Cutshaw, Saji Uthaman, Nora Hassan, Siddhant Kothadiya, Xiaona Wen, Rizia Bardhan Chemical Reviews.2023; 123(13): 8297. CrossRef
Current insights on the roles of gut microbiota in inflammatory bowel disease-associated extra-intestinal manifestations: pathophysiology and therapeutic targets Yizhe Tie, Yongle Huang, Rirong Chen, Li Li, Minhu Chen, Shenghong Zhang Gut Microbes.2023;[Epub] CrossRef
Comments on Efficacy of a Synbiotic Containing Lactobacillus paracasei DKGF1 and Opuntia humifusa in Elderly Patients with Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial Kwang Woo Kim Gut and Liver.2023; 17(6): 954. CrossRef
Evaluation of gut dysbiosis using serum and fecal bile acid profiles Tadakuni Monma, Junichi Iwamoto, Hajime Ueda, Makoto Tamamushi, Fumio Kakizaki, Naoki Konishi, Shoichiro Yara, Teruo Miyazaki, Takeshi Hirayama, Tadashi Ikegami, Akira Honda World Journal of Clinical Cases.2022; 10(34): 12484. CrossRef
Jim O’Connell, Jayne Doherty, Amy Buckley, David Cormican, Cara Dunne, Karen Hartery, John Larkin, Finbar MacCarthy, Paul McCormick, Susan McKiernan, Brian Mehigan, Cian Muldoon, Ciara Ryan, Jacintha O’Sullivan, David Kevans
Intest Res 2022;20(3):381-385. Published online March 11, 2022
Role of Oncostatin M in the prognosis of inflammatory bowel disease: A meta-analysis Yue Yang, Kan-Zuo Fu, Gu Pan World Journal of Gastrointestinal Surgery.2024; 16(1): 228. CrossRef
Tryptanthrin Down-Regulates Oncostatin M by Targeting GM-CSF-Mediated PI3K-AKT-NF-κB Axis Na-Ra Han, Hi-Joon Park, Seong-Gyu Ko, Phil-Dong Moon Nutrients.2024; 16(23): 4109. CrossRef
Yoo Jin Lee, Seong-Eun Kim, Yong Eun Park, Ji Young Chang, Hyun Joo Song, Duk Hwan Kim, Young Joo Yang, Byung Chang Kim, Jae Gon Lee, Hee Chan Yang, Seung-Jae Myung, Clinical Practice Guideline Committee of the Korean Association for the Study of Intestinal Diseases
Intest Res 2022;20(3):386-388. Published online March 11, 2022